Brief: Radiopharm Theranostics To Meet With U.S. FDA To Align On Pivotal Phase 3 Trial Design For Rad 101 In Diagnosis Of Brain Metastases
17/08/2026 13:37
BRIEF-Radiopharm Theranostics To Meet With U.S. FDA To Align On Pivotal Phase 3 Trial Design For Rad 101 In Diagnosis Of Brain Metastases Radiopharm Theranostics Ltd RAD.AX:
RADIOPHARM THERANOSTICS TO MEET WITH U.S. FDA TO ALIGN ON PIVOTAL PHASE 3 TRIAL DESIGN FOR RAD 101 IN DIAGNOSIS OF BRAIN METASTASES
RADIOPHARM THERANOSTICS - RAD101 RECEIVES FDA FAST TRACK DESIGNATION FOR BRAIN METASTASES DIAGNOSIS
RADIOPHARM THERANOSTICS - SCHEDULES END-OF-PHASE 2 FDA MEETING FOR RAD101 PHASE 3 TRIAL ON OCT 1, 2026
Source text: ID:nGNX7P6Yh
Further company coverage: RAD.AX
Recent news on Radiopharm Theranostics
See all newsNASDAQ RESUMED AT 09:47 AM
NASDAQ TRADE HALT VOLATILITY TRADING PAUSE AT 09:42 AM
Brief: Radiopharm Theranostics To Meet With U.S. FDA To Align On Pivotal Phase 3 Trial Design For Rad 101 In Diagnosis Of Brain Metastases
NASDAQ RESUMED AT 09:56 AM
NASDAQ TRADE HALT CONTINUES VOLATILITY TRADING PAUSE AT 09:50 AM